Observed Signal · Nov 4, 2026 · Earnings Report · Source: PR Newswire: Advertising & Marketing · Impact: 1/5 · Sentiment: Positive
Sera Prognostics Reports Q3 2026 Results
Sera Prognostics, a diagnostics company focused on pregnancy health, reported third-quarter 2026 financial results. PreTRM test volume increased 54% sequentially, and revenue reached $42,000, a 163% year-over-year increase. The company's net loss was $8.05 million for the quarter. Florida became the second state to provide Medicaid coverage for the PreTRM test, expanding to approximately 7 million covered lives. The company also initiated CE Mark submission for its PreTRM Global test in Europe and expanded its sales team by 25%.
Quarterly earnings report from a niche diagnostics company with no direct impact on AdTech, MarTech, or advertising industry.
Track Real-Time Financials Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- PreTRM test volume increased 54% sequentially in Q3 2026
- Q3 2026 revenue was $42,000, up 163% year-over-year
- Florida became the second Medicaid state to cover PreTRM
- CE Mark submission for PreTRM Global started in Europe
- Sales team expanded by 25% in Q3 2026
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Genomma Lab Reports Q3 2026 Results
Genomma Lab Internacional announced its Q3 2026 financial results. Consolidated net sales grew 1.3% to MXN 4,497.6 million, with Latin America up 12.2%, while Mexico continued its recovery with sell-out returning to growth. EBITDA margin was 21.0%, down 271 basis points year-over-year due to strategic investments in promotions and commercial spending. Net income rose 18.6% to MXN 514.9 million, driven by lower financing costs and favorable FX. The company highlighted a new product innovation driving 39% sell-out growth and Suerox reaching a record 12.6% value share. Genomma plans to present its new operating model and AI platform at an Investor Day in New York on December 3, 2026.
Caris Life Sciences Reports Q3 2026 Results, Raises Guidance
Caris Life Sciences, a Nasdaq-listed TechBio company, reported third-quarter 2026 financial results with total revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling services. The company completed approximately 61,500 clinical cases, up 21%, and processed over 358,000 oncology tests. Net income was $15.3 million, and Adjusted EBITDA reached $44.4 million. Caris raised its full-year 2026 revenue guidance to $1.04-$1.05 billion, representing 28-29% growth. Operational highlights include the launch of Caris Assure Therapy Response Monitoring, an enhanced Caris Assure for therapy selection, a $100 million share repurchase program, and two national advertising campaigns featuring Kevin Costner and Jordan Spieth. The company also surpassed 1.2 million total profiles and over 849,000 whole transcriptome profiles.
Penumbra Q3 2026 Results Strong, Acquisition Pending
Penumbra, a thrombectomy company, reported strong Q3 2026 results with revenue of $410.1M, up 15.6% year-over-year. Global thrombectomy revenue grew 18.1% to $279.2M, while embolization and access revenue rose 10.8%. Net income was $42.3M. The company highlighted a pending acquisition by Boston Scientific Corporation, which incurred $7.1M in acquisition-related expenses. Due to the pending deal, Penumbra will not provide full-year guidance or host a conference call. The acquisition is subject to regulatory approvals and other conditions.
Receive all future signals for Financials in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.